Kapecitabin

Kapecitabin
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	45-60 minuta
Izlučivanje	Renalno 95.5%
Identifikatori
CAS broj	154361-50-9
ATC kod	L01BC06 (WHO)
PubChem	CID 60953
DrugBank	DB01101
ChemSpider	54916
KEGG	C12650
ChEBI	CHEBI:31348
ChEMBL	CHEMBL1773
Hemijski podaci
Formula	C15H22FN3O6
Molarna masa	359,350
	SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O; ;
	InChI InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 ; Key:GAGWJHPBXLXJQN-UORFTKCHSA-N ;
Fizički podaci
Tačka topljenja	110—121 °C (230—250 °F)

Kapecitabin je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 359,350 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine уреди

Osobina	Vrednost
Broj akceptora vodonika	7
Broj donora vodonika	3
Broj rotacionih veza	7
Particioni koeficijent^[9] (ALogP)	0,8
Rastvorljivost^[10] (logS, log(mol/L))	-3,8
Polarna površina^[11] (PSA, Å²)	120,7

Reference уреди

^ Walko, C. M.; Lindley, C. (јануар 2005). „Capecitabine: A review”. Clinical Therapeutics. 27 (1): 23—44. PMID 15763604. doi:10.1016/j.clinthera.2005.01.005.
^ Wagstaff AJ; Ibbotson, T.; Goa, K. L. (2003). „Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer”. Drugs. 63 (2): 217—36. PMID 12515569. doi:10.2165/00003495-200363020-00009.
^ Koukourakis, G. V.; Kouloulias, V.; Koukourakis, M. J.; Zacharias, G. A.; Zabatis, H.; Kouvaris, J. (2008-08-27). „Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: A review”. Molecules (Basel, Switzerland). 13 (8): 1897—922. PMC 6245068  . PMID 18794792. doi:10.3390/molecules13081897  .
^ Twelves, C. (2001). „Vision of the future: Capecitabine”. The Oncologist. 6 Suppl 4: 35—39. PMID 11585973. S2CID 25077953. doi:10.1634/theoncologist.6-suppl_4-35.
^ Milano, G.; Ferrero, J. M.; François, E. (2004-08-16). „Comparative pharmacology of oral fluoropyrimidines: A focus on pharmacokinetics, pharmacodynamics and pharmacomodulation”. British Journal of Cancer. 91 (4): 613—7. PMC 2364788  . PMID 15280932. doi:10.1038/sj.bjc.6601973.
^ De Bono, J. S.; Twelves, C. J. (2001). „The oral fluorinated pyrimidines”. Investigational New Drugs. 19 (1): 41—59. PMID 11291832. S2CID 5691855. doi:10.1023/a:1006404701008.
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709  . PMID 21059682. doi:10.1093/nar/gkq1126.
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889  . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura уреди

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze уреди

Capecitabine

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Walko, C. M.; Lindley, C. (јануар 2005). „Capecitabine: A review”. Clinical Therapeutics. 27 (1): 23—44. PMID 15763604. doi:10.1016/j.clinthera.2005.01.005.

[2] Wagstaff AJ; Ibbotson, T.; Goa, K. L. (2003). „Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer”. Drugs. 63 (2): 217—36. PMID 12515569. doi:10.2165/00003495-200363020-00009.

[3] Koukourakis, G. V.; Kouloulias, V.; Koukourakis, M. J.; Zacharias, G. A.; Zabatis, H.; Kouvaris, J. (2008-08-27). „Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: A review”. Molecules (Basel, Switzerland). 13 (8): 1897—922. PMC 6245068  . PMID 18794792. doi:10.3390/molecules13081897  .

[4] Twelves, C. (2001). „Vision of the future: Capecitabine”. The Oncologist. 6 Suppl 4: 35—39. PMID 11585973. S2CID 25077953. doi:10.1634/theoncologist.6-suppl_4-35.

[5] Milano, G.; Ferrero, J. M.; François, E. (2004-08-16). „Comparative pharmacology of oral fluoropyrimidines: A focus on pharmacokinetics, pharmacodynamics and pharmacomodulation”. British Journal of Cancer. 91 (4): 613—7. PMC 2364788  . PMID 15280932. doi:10.1038/sj.bjc.6601973.

[6] De Bono, J. S.; Twelves, C. J. (2001). „The oral fluorinated pyrimidines”. Investigational New Drugs. 19 (1): 41—59. PMID 11291832. S2CID 5691855. doi:10.1023/a:1006404701008.

[7] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709  . PMID 21059682. doi:10.1093/nar/gkq1126.

[8] David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889  . PMID 18048412. doi:10.1093/nar/gkm958.

[9] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[10] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[11] Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]